These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10831076)

  • 21. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cytomegalovirus and kidney transplantation: a clinician's update.
    De Keyzer K; Van Laecke S; Peeters P; Vanholder R
    Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus infection after liver transplantation: current concepts and challenges.
    Razonable RR
    World J Gastroenterol; 2008 Aug; 14(31):4849-60. PubMed ID: 18756591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients.
    Kletzmayr J; Kreuzwieser E; Watkins-Riedel T; Berlakovich G; Kovarik J; Klauser R
    Transplantation; 2000 Oct; 70(8):1174-80. PubMed ID: 11063336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
    Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors.
    Rondeau E; Bourgeon B; Peraldi MN; Lang P; Buisson C; Schulte KM; Weill B; Sraer JD
    Transpl Int; 1992; 5 Suppl 1():S30-1. PubMed ID: 14621725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.
    Gabardi S; Magee CC; Baroletti SA; Powelson JA; Cina JL; Chandraker AK
    Pharmacotherapy; 2004 Oct; 24(10):1323-30. PubMed ID: 15628830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir.
    Turgeon N; Fishman JA; Doran M; Basgoz N; Tolkoff-Rubin NE; Cosimi AB; Rubin RH
    Transpl Infect Dis; 2000 Mar; 2(1):2-10. PubMed ID: 11429003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Failure of ganciclovir prophylaxis of primary cytomegalovirus disease in immunologic high-risk recipients.
    Conti DJ; Isenberg A; Shen GK; Hahn A; Singh TP
    Transplant Proc; 1998 Jun; 30(4):1314-5. PubMed ID: 9636533
    [No Abstract]   [Full Text] [Related]  

  • 32. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.
    Gruber SA; Garnick J; Morawski K; Sillix DH; West MS; Granger DK; El-Amm JM; Alangaden GJ; Chandrasekar P; Haririan A
    Clin Transplant; 2005 Apr; 19(2):273-8. PubMed ID: 15740567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs and consequences of cytomegalovirus disease.
    Schnitzler MA
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of ganciclovir prophylaxis on cytomegalovirus infection in recipients of cadaveric renal allografts.
    Ram Peddi V; Hariharan S; Schroeder TJ; First MR
    Nephron; 1997; 76(1):49-55. PubMed ID: 9171300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants.
    Sawyer MD; Mayoral JL; Gillingham KJ; Kramer MA; Dunn DL
    Arch Surg; 1993 Feb; 128(2):165-9; discussion 170. PubMed ID: 8381646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.